Crewe Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History
Crewe Advisors LLC
- $1.01 Billion
- Q4 2025
A detailed history of Crewe Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 88 shares of APLS stock, worth $1,789. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88
Previous 88
-0.0%
Holding current value
$1,789
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
330Shares Held
124MCall Options Held
4.12MPut Options Held
756K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...